EMERALD trial
Switching to Symtuza for HIV Maintains High Virologic Suppression Without Drug Resistance
Changing the treatment regimen of adults with HIV who had suppressed viral loads to Symtuza did not increase their ...
NOVEMBER 16, 2018
Switching to a D/C/F/TAF Regimen
Gregory D. Huhn, MD, discusses an analysis of 48-week data from the EMERALD trial in subgroups based on age, gender ...
MAY 30, 2018
Single-Tablet Combo as Effective as Current HIV Treatment
If approved in the U.S., D/C/F/TAF would be the only complete regimen that could deliver the potential adherence ...
OCTOBER 11, 2017
Load more